Interstitial Lung Disease / Pulmonary Fibrosis Secondary to Rheumatoid Arthritis (Service-Connected)
Interstitial Lung Disease / Pulmonary Fibrosis can develop as a service-connected secondary condition to Rheumatoid Arthritis (Service-Connected) when a medical nexus links the two under 38 CFR § 3.310. The strength of medical evidence for this specific pairing is strong. Rheumatoid arthritis (RA) is a systemic autoimmune disease that produces extra-articular manifestations in 40% of patients, with the lungs being the most common extra-articular target.
How is Interstitial Lung Disease / Pulmonary Fibrosis connected to Rheumatoid Arthritis (Service-Connected)?
Rheumatoid arthritis (RA) is a systemic autoimmune disease that produces extra-articular manifestations in 40% of patients, with the lungs being the most common extra-articular target. RA-associated interstitial lung disease (RA-ILD) develops when the same immune dysregulation driving synovial inflammation — autoantibody production (RF, anti-CCP), Th1/Th17 activation, and pro-inflammatory cytokine release (TNF-alpha, IL-6) — targets the pulmonary interstitium. Immune complexes deposit in the alveolar capillary membrane, triggering macrophage activation and fibroblast proliferation that produces progressive pulmonary fibrosis. The usual interstitial pneumonia (UIP) pattern predominates, identical histologically to idiopathic pulmonary fibrosis. RA-ILD develops in 10-30% of RA patients and is the second leading cause of death in RA after cardiovascular disease.
“Disability which is proximately due to or the result of a service-connected disease or injury shall be service connected.”
What evidence supports claiming Interstitial Lung Disease / Pulmonary Fibrosis as secondary to Rheumatoid Arthritis (Service-Connected)?
Bongartz T et al. (2010) Arthritis Rheum (RA-associated interstitial lung disease — incidence and mortality); Olson AL et al. (2011) Am J Respir Crit Care Med (RA-ILD prevalence and prognosis).
How do I file a secondary claim for Interstitial Lung Disease / Pulmonary Fibrosis?
High-resolution chest CT demonstrating interstitial lung disease pattern (ground-glass opacities, honeycombing, traction bronchiectasis). Pulmonary function tests showing restrictive pattern with reduced DLCO. Rheumatology and pulmonology records documenting RA diagnosis preceding ILD. Rheumatology nexus letter addressing systemic autoimmune mechanism. If methotrexate is used for RA, the nexus letter should address whether ILD is disease-related or medication-related (both are valid secondary pathways). Consider under DC 6825 (diffuse interstitial fibrosis) — severe ILD with DLCO <40% predicted can warrant 100% rating.
How does the VA rate Interstitial Lung Disease / Pulmonary Fibrosis?
Interstitial Lung Disease / Pulmonary Fibrosis is rated under 38 CFR Part 4 using the diagnostic code assigned to that condition. The VA evaluates the severity of the secondary condition independently and assigns a rating from 0% to 100% in increments defined in the rating schedule. That rating is then combined with Rheumatoid Arthritis (Service-Connected) and all other service-connected conditions using the combined ratings formula under § 4.25.
Interstitial Lung Disease / Pulmonary Fibrosis is rated under DC 6825 in 38 CFR Part 4.
Common Questions — Interstitial Lung Disease / Pulmonary Fibrosis Secondary to Rheumatoid Arthritis (Service-Connected)
Can Interstitial Lung Disease / Pulmonary Fibrosis be claimed as secondary to Rheumatoid Arthritis (Service-Connected)?
Yes. Under 38 CFR § 3.310(a), any disability proximately caused or chronically worsened by a service-connected condition is itself service-connected. Interstitial Lung Disease / Pulmonary Fibrosis is a documented secondary pairing for Rheumatoid Arthritis (Service-Connected) with strong medical evidence. A nexus letter from a qualified physician linking the two conditions is the most reliable way to establish this connection.
What evidence proves Interstitial Lung Disease / Pulmonary Fibrosis is caused by Rheumatoid Arthritis (Service-Connected)?
The gold standard is a private nexus opinion stating — to at least a 50% probability ("at least as likely as not") — that the secondary condition was caused or aggravated by the primary service-connected condition. Peer-reviewed medical literature supporting the physiological mechanism strengthens the nexus. Treatment records documenting the onset or worsening of the secondary condition in temporal relation to the primary are supporting evidence.
Does the VA combine or separately rate Interstitial Lung Disease / Pulmonary Fibrosis?
The VA rates Interstitial Lung Disease / Pulmonary Fibrosis separately under its own 38 CFR Part 4 diagnostic code, then combines it with Rheumatoid Arthritis (Service-Connected) and all other service-connected ratings using the combined ratings formula under § 4.25. The formula applies the whole-person concept: a 50% combined existing rating plus a new 30% rating yields 65% (rounded to 70%), not 80%.
What legal standard applies to secondary service connection?
38 CFR § 3.310(a) states: "Disability which is proximately due to or the result of a service-connected disease or injury shall be service connected." The aggravation variant under § 3.310(b) applies where the primary condition permanently worsens a pre-existing disability beyond its natural progression. Both standards require a showing of nexus — a medical or scientific link between the primary condition and the secondary.
How strong is the medical evidence for this pairing?
The medical evidence supporting Interstitial Lung Disease / Pulmonary Fibrosis as secondary to Rheumatoid Arthritis (Service-Connected) is rated strong. Rheumatoid arthritis (RA) is a systemic autoimmune disease that produces extra-articular manifestations in 40% of patients, with the lungs being the most common extra-articular target. RA-associated interstitial lung disease (RA-ILD) develops when the same immune dysregulation driving synovial inflammation — autoantibody production (RF, anti-CCP), Th1/Th17 activation, and pro-inflammatory cytokine release (TNF-alpha, IL-6) — targets the pulmonary interstitium. Immune complexes deposit in the alveolar capillary membrane, triggering macrophage activation and fibroblast proliferation that produces progressive pulmonary fibrosis. The usual interstitial pneumonia (UIP) pattern predominates, identical histologically to idiopathic pulmonary fibrosis. RA-ILD develops in 10-30% of RA patients and is the second leading cause of death in RA after cardiovascular disease.
Do I need a nexus letter for a secondary claim?
The VA will not solicit nexus evidence on your behalf for secondary claims. In practice, a written nexus opinion from a private physician or independent medical examiner is essential — the VA's Compensation & Pension (C&P) examiner is not required to produce a favorable nexus opinion, and the VA has discretion to weigh competing opinions. Submitting a private nexus letter at the time of filing is the most reliable strategy.
Get a Full Secondary Condition Analysis
VeteranHQ cross-references your complete medical history against the full secondary condition database, surfacing every secondary claim opportunity for your specific service-connected conditions.
Start Your Free Analysis